NCT06071923

Brief Summary

Aims of the Research

  1. 1.To detect correlation between hyperthyroidism and non alcoholic fatty liver disease (NAFLD).
  2. 2.To detect hepatic risk in subclinical and clinical hypothyroidism .
  3. 3.To detect early liver disorders in thyroid disorders using fibroscan .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
140

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 2, 2023

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 10, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
Last Updated

October 10, 2023

Status Verified

October 1, 2023

Enrollment Period

1 year

First QC Date

October 2, 2023

Last Update Submit

October 6, 2023

Conditions

Fatty Liver Disease

Outcome Measures

Primary Outcomes (1)

  • Detect correlation between hyperthyroid diseases and NASH .

    Test the patients of thyroid disorders for metabolic fatty liver changes

    Baseline

Interventions

FibroscanDEVICE

Scan the liver for metabolic fatty changes

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with thyroid disorders and age above 18 years

You may qualify if:

  • The study will include thyroid patients over one year duration ( age above 18 years old

You may not qualify if:

  • History of liver failure or patient known to have congenital liver disease.
  • Medications associated with weight gain .
  • Patients who have diabetes mellitus.
  • patients who already have liver disease eg; chronic viral hepatitis, liver cirrhosis.
  • Patients on antistatin.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Non-alcoholic Fatty Liver Disease

Condition Hierarchy (Ancestors)

Fatty LiverLiver DiseasesDigestive System Diseases

Central Study Contacts

Tasneem Mohammed Ali, Master

CONTACT

01098704665Tonamohammed96@gmail.com

Hanan Mahmoud, Prof dr

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 2, 2023

First Posted

October 10, 2023

Study Start

January 1, 2024

Primary Completion

January 1, 2025

Study Completion

February 1, 2025

Last Updated

October 10, 2023

Record last verified: 2023-10